Retifanlimab Plus Carboplatin Meets PFS End Point in Metastatic SCAC - Cancer Network
Retifanlimab with carboplatin and paclitaxel showed significant progression-free survival vs placebo in metastatic SCAC patients, with a median PFS of 9.3 months vs 7.4 months (HR, 0.63; P = .0006). Retifanlimab also improved overall response rate and overall survival.
Related Clinical Trials
Reference News
Retifanlimab plus platinum-based chemotherapy showed a 37% reduction in risk of progression or death in patients with squamous cell anal carcinoma, with median progression-free survival of 9.3 months vs 7.4 months in the placebo group, according to the phase III POD1UM-303/InterAACT2 trial.
Retifanlimab (Zynyz) combined with chemotherapy improved progression-free survival (PFS) to 9.3 months vs. 7.4 months with placebo in treatment-naïve patients with advanced squamous cell carcinoma of the anal canal (SCAC), according to a phase III trial. Median overall survival (OS) was 29.2 months with retifanlimab vs. 23.0 months with placebo, showing a strong trend toward improved OS. Retifanlimab plus carboplatin and paclitaxel represents a new standard of care for advanced SCAC.
Retifanlimab with carboplatin and paclitaxel showed significant progression-free survival vs placebo in metastatic SCAC patients, with a median PFS of 9.3 months vs 7.4 months (HR, 0.63; P = .0006). Retifanlimab also improved overall response rate and overall survival.